This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Ologen (OculusGen)-Glaucoma and Pterygium Historical Control Study in Beijing Remin Hospital

This study has been completed.
Information provided by:
Pro Top & Mediking Company Limited Identifier:
First received: May 1, 2006
Last updated: May 21, 2008
Last verified: May 2008
The purpose of this study is to determine whether the ologen (OculusGen) Collagen Matrix is effective and safe to implant as an aid of glaucoma and pterygium surgeries.

Condition Intervention Phase
Glaucoma Pterygium Device: OculusGen Biodegradable Collagen Matrix Implant Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Study of the Safety and Effectiveness of the OculusGen Collagen Matrix Implant as an Aid in Glaucoma and Pterygium Surgery

Resource links provided by NLM:

Further study details as provided by Pro Top & Mediking Company Limited:

Primary Outcome Measures:
  • 1. the effectiveness via the reduction of IOP and the incidence of pterygium recurrence [ Time Frame: 180 day ]

Secondary Outcome Measures:
  • the safety via the incidence of complications and adverse events. [ Time Frame: 180 day ]

Estimated Enrollment: 60
Study Start Date: December 2005
Primary Completion Date: January 2008 (Final data collection date for primary outcome measure)
Detailed Description:
ologen (OculusGen) Collagen Matrix is a porous, scaffold matrix. It is to be implanted on the top of the scleral flap and beneath the conjunctiva and Tenon's capsule at the end of trabeculectomy. The pores in the scaffold matrix range from 20 to 200µm, a size that is suitable for fibroblasts to grow randomly, through the body of the matrix without causing scarring. The space occupied by the collagen matrix scaffold creates room for the development of a filtration bleb. Immediately after implantation, the collagen matrix is absorbed with the aqueous humor that bring a certain pressure press on the top of scleral flap which makes the dynamic balance for the aqueous system to keep the IOP in the right side. The collagen matrix is bio-degraded within 90 days and will leave a physiologic space for the filtration bleb to facilitate control of intraocular pressure (IOP).

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 18 years or over
  • Patient able to cooperate with study procedures and able to perform tests reliably
  • Patient willing to sign informed consent
  • Patient able and willing to complete postoperative follow-up requirements
  • Glaucoma:one/both eyes are affected by glaucoma
  • Pterygium: patient with pterygium

Exclusion Criteria:

  • Known allergic reactions to collagen
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00321035

Renmin Hospital of Beijing University
Beijing, China, 100044
Sponsors and Collaborators
Pro Top & Mediking Company Limited
Principal Investigator: Xiao-Xin Li, MD Renmin Hospital of Beijing University
  More Information

Publications: Identifier: NCT00321035     History of Changes
Other Study ID Numbers: Mediking0501-1
Study First Received: May 1, 2006
Last Updated: May 21, 2008

Keywords provided by Pro Top & Mediking Company Limited:
collagen matrix
anti scarring
prevent recurrence
tissue engineering
Aeon Astron

Additional relevant MeSH terms:
Ocular Hypertension
Eye Diseases
Conjunctival Diseases processed this record on September 19, 2017